Status:
UNKNOWN
Low Dose Atropine for Symptomatic Vitreous Floaters
Lead Sponsor:
Jeanette Du
Conditions:
Vitreous Floaters
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NE...
Eligibility Criteria
Inclusion
- Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants.
Exclusion
- Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06174935
Start Date
January 1 2024
End Date
June 1 2024
Last Update
December 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Group of Washington
Reston, Virginia, United States, 20190